BAT Subsidiary WITCO: Vuse Has Strong Positive Impact on Revenue

Regulations by 2FIRSTS.ai
Apr.24.2024
BAT Subsidiary WITCO: Vuse Has Strong Positive Impact on Revenue
WITCO CEO Raoul Glynn announced at a press conference that Vuse e-cigarettes will positively impact company revenue.

According to a report by Newsday on April 24th, Raoul Glynn, CEO of West Indies Tobacco Company Limited (WITCO), announced at a press conference held at the Queen's Hall in Spain on April 23rd that the e-cigarette brand Vuse will have a strong and positive impact on the company's revenue.

 

The quality of Vuse products surpasses that of other brands on the market, with attractive prices and a strong profit structure. Witco's advantage lies in its distribution and ability to obtain the necessary products, which is what we value.

 

Greene stated that approximately 12% of consumers in the market are using e-cigarette products. "We anticipated changes in the market and observed e-cigarettes growing in a way that does not decrease tobacco sales."

 

Last week, the company revealed that as of December 31, 2023, its annual revenue had increased by 5.9% compared to the previous year. The company's financial director, Johan Grosberg, stated that despite taking many measures to improve operational efficiency last year, increased costs of raw materials, packaging, and labor led to an increase in sales costs. However, they were able to benefit from reduced expenses.

 

The brand support expenses align with our marketing plan, allowing us to trim slightly and execute the plan more effectively. Additionally, as part of a large group, we benefit from some restructuring taking place outside of the group.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Russia to Start Extrajudicial Blocking of Sites Selling Tobacco and Nicotine Products Online From March 1
Russia to Start Extrajudicial Blocking of Sites Selling Tobacco and Nicotine Products Online From March 1
Russia will introduce an extrajudicial (non-court) blocking mechanism starting March 1, 2026, allowing authorities to block websites selling tobacco and nicotine-containing products online without a court order. State Duma member Anton Nemkin said the change will place offending sites directly onto the prohibited information registry, speeding up enforcement, reducing the court burden, and increasing platform obligations to proactively monitor content.
Jan.29 by 2FIRSTS.ai
BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
BAT FY2025 Results: New Categories Contribution Expands as Smokeless Share Reaches 18.2%
British American Tobacco reported FY2025 revenue of £25.61 billion, down 1.0% on a reported basis but up 2.1% at constant currency. New Categories revenue rose 5.5%, with category contribution increasing 77%. Smokeless products accounted for 18.2% of group revenue.
Feb.12
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
BAT Kenya says it has resumed sales of Velo oral nicotine pouches after receiving regulatory clarity, reinforcing its push into non-combustible products as cigarette consumption falls.The company reported a 10% drop in turnover in 2025, with revenue closing at KSh23.2 billion (about $178.64 million), largely attributed to the growing presence of illegal tobacco products.
Mar.03 by 2FIRSTS.ai
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03
3,200 suspected "drug-laced cigarettes" seized in Johor Bahru, case value estimated at US$242,500
3,200 suspected "drug-laced cigarettes" seized in Johor Bahru, case value estimated at US$242,500
Malaysian police seized 3,200 suspicious e-pods with ketamine liquid, arresting two men in Johor Bahru's drug distribution bust.
Feb.04 by 2FIRSTS.ai